News
IMI Info Day- 5th call proposals (Brussels, 27 February 2012)
The Innovative Medicines Initiative (IMI) is Europe's largest public-private partnership that fosters improvement of the drug development process by supporting a more efficient discovery and development of better and safer medicines for patients. This €2 billion-budget initiative supports collaborative research projects in addition to building networks of industrial and academic experts in Europe that will boost innovation in healthcare.
IMI held an Open Info Day on its 5th Call for proposals at the Crowne Plaza - Le Palace Hotel in Brussels, Belgium on Monday 27 February 2012.
The programme included:
- an overview of IMI’s funding and intellectual property (IP) rules,
- tips and testimonies from people involved in ongoing IMI projects
- a presentation of the 5th Call topic ‘European lead factory: Joint European compound library and screening centre’ by the Project Coordinator.
- networking opportunities. (IMI staff were available to answer questions)
IMI warmly encourages small and medium-sized enterprises, patient organisations, regulatory authorities, academic teams, industry, hospitals and other organisations with an interest in IMI projects to take part in the Open Info Day.
Please click hereafter to download the agenda
For the first time, the registration tool allowed participants to network with one another and arrange meetings before the event. Participation in the event was free.
Note on IMI's 5th Call for proposals
IMI's 5th Call for proposals currently includes one indicative topic:
- European lead factory: Joint European compound library and screening centre
Please click hereafter in order to download an outline of the proposed European lead factory topic
More information on the indicative call topic is availble on the IMI website. Please note that all information relating to the 5th Call is indicative and subject to change. Final information about the IMI 5th Call is to be communicated after approval by the IMI Governing Board.
IMI is set to provide socio-economic benefits to European citizens, to increase Europe's competitiveness globally as well as to establish Europe as the most attractive place for pharmaceutical R&D. IMI supports research projects in the areas of safety and efficacy, knowledge management and education and training. Furthermore, IMI is aiming at a more collaborative ecosystem for pharmaceutical research and development (R&D). Projects are selected through open Calls for proposals.
The research consortia participating in IMI projects consist of:
- large biopharmaceutical companies that are members of EFPIA,
- and a variety of other partners, such as:
- small- and medium-sized enterprises,
- patients' organisations,
- universities and other research organisations,
- hospitals,
- regulatory agencies,
- any other industrial partners
IMI is a Joint Undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA).